Ozempic is probably the name of the drug that many people know because over the past three years it has been used to lose weight quickly. Not many people realize that besides Ozempic, there is also Wegovy that provides the same effect.
High demand has led to the development of better "obesity drugs" being enhanced by pharmaceutical companies. Eli Lilly is not left behind and has published the results of their latest obesity drug test that can reduce up to 30% of the body weight of its users.
The drug Retatrudide combines the hormone GLP-1 with the hormones GIP and glucagon to increase the level of efficacy. In the 68-week TRIUMPH-4 clinical trial, which had 445 participants, they were divided into three groups. The first group took a placebo while the other two groups took Retatrudide at two different doses.
The group taking the highest dose of Retatrudide recorded an average weight loss of 28.4% with some losing more than 32 kg. The second group with a lower dose recorded an average weight loss of 26.4%. The placebo control group only achieved an average weight loss of 2.1%. In addition to weight loss, participants also reported reduced knee pain.
The weight loss percentage in this clinical trial is higher than the 22.1% average weight loss reported by Eli Lilly in January. More data from this clinical trial will be published starting next year, with the hope that it could enter the market in a short period of time.
Although Retatrudide is effective in weight loss, it comes with side effects such as nausea and diarrhea. These are the same side effects reported by users of Ozempic and Wegovy.